Exciting Developments in Amplia Therapeutics' ACCENT Trial
HIGHLIGHTS
- An additional confirmed partial response has been recorded in the ongoing ACCENT trial.
- This brings the confirmed Objective Response Rate to 35%.
- Updated data to be presented at the Life Sciences Virtual Investor Forum.
Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) has recently made an exciting announcement regarding their ongoing ACCENT trial in metastatic pancreatic cancer. An additional confirmed partial response (PR) has been achieved, showcasing their commitment to innovative cancer therapies.
Significant Findings and Future Presentations
The confirmed objective response rate (ORR) has now reached 35%, which stands out against the 23% ORR recorded for gemcitabine and nab-paclitaxel alone in the benchmark MPACT trial. This remarkable improvement emphasizes the potential of Amplia's FAK inhibitor, narmafotinib, when combined with these chemotherapies.
The results will be highlighted in an upcoming presentation at the Life Sciences Virtual Investor Forum. Here, Amplia's CEO, Dr. Chris Burns, will share insights and further details about the ongoing ACCENT trial.
Understanding the Role of FAK Inhibitors
Amplia Therapeutics is making strides in the pharmaceutical industry with its focus on Focal Adhesion Kinase (FAK) inhibitors. FAK has emerged as a pivotal target in cancer treatment, especially in fibrotic cancers such as pancreatic and ovarian cancers. Its involvement in chronic conditions, such as idiopathic pulmonary fibrosis (IPF), adds another layer of significance to the research and development involved.
About Narmafotinib and Its Progress
Narmafotinib (AMP945) is Amplia’s premier FAK inhibitor and is currently being investigated in the ACCENT trial. This highly potent and selective drug has demonstrated promising results in various preclinical cancer studies. As the clinical trial progresses, it has already surpassed its primary endpoint with an impressive confirmed response rate of 35%, compared to the MPACT study's findings.
Additionally, an interim median progression-free survival (PFS) of 7.6 months has been reported. A second trial, AMPLICITY, is also underway, focusing on the combination of narmafotinib with chemotherapy treatments for patients with advanced pancreatic cancer.
Investor and Media Contact Information
For inquiries, Dr. Chris Burns, CEO of Amplia Therapeutics, is available for contact at chris@ampliatx.com. For U.S. inquiries, Robert Giordano can be reached at rjgiordano@ggrouplifesciences.com or +1 917 327 3938. For media inquiries, Haley Chartres from H^CK is your point of contact via haley@hck.digital or +61 423 139 163.
Frequently Asked Questions
What is the significance of the ACCENT trial results?
The results indicate a 35% objective response rate, showing promise for the effectiveness of narmafotinib in combination therapies for pancreatic cancer.
Who is leading the ACCENT trial?
The ACCENT trial is being led by Amplia Therapeutics, under the guidance of their CEO, Dr. Chris Burns.
What is the role of FAK in cancer treatment?
FAK is a crucial target in cancer, particularly in fibrotic cancers, and contributes to the understanding of cancer progression and treatment efficacy.
How can I learn more about Amplia Therapeutics?
You can visit their official website at www.ampliatx.com for more information on their research and pipeline.
What are the next steps for Amplia Therapeutics?
Amplia will continue to present their findings and advance their clinical trials, particularly the ongoing ACCENT and AMPLICITY studies.
